Cargando…

Effectiveness of mepolizumab in severe asthma in Japan: A real‐world study using claims data

Detalles Bibliográficos
Autores principales:	Nagase, Hiroyuki, Tamaoki, Jun, Suzuki, Takeo, Nezu, Yasuko, Katsumata, Masayuki, Komatsubara, Masaki, Mu, George, Yang, Shibing, Cole, Ashley L., Alfonso‐Cristancho, Rafael
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8694177/ https://www.ncbi.nlm.nih.gov/pubmed/34708944 http://dx.doi.org/10.1002/clt2.12063

Ejemplares similares

Mepolizumab decreased the levels of serum galectin-10 and eosinophil cationic protein in asthma
por: Kobayashi, Konomi, et al.
Publicado: (2021)

Mepolizumab improves work productivity, activity limitation, symptoms, and rescue medication use in severe eosinophilic asthma
por: Albers, Frank C., et al.
Publicado: (2022)

Remission outcomes in severe eosinophilic asthma with mepolizumab therapy: Analysis of the REDES study
por: Pavord, Ian, et al.
Publicado: (2023)

Efficacy of mepolizumab for patients with severe asthma and eosinophilic chronic rhinosinusitis
por: Numata, Takanori, et al.
Publicado: (2019)

Severe Pediatric Asthma Therapy: Mepolizumab
por: Ullmann, Nicola, et al.
Publicado: (2022)

Real-world mepolizumab in the prospective severe asthma REALITI-A study: initial analysis
por: Harrison, Tim, et al.
Publicado: (2020)

Clinical usefulness of mepolizumab in severe eosinophilic asthma
por: Menzella, Francesco, et al.
Publicado: (2016)

May mepolizumab used in asthma correct subfertility?
por: Ozden, Guzin, et al.
Publicado: (2021)

Efficacy of add-on mepolizumab in adolescents with severe eosinophilic asthma
por: Yancey, Steven W., et al.
Publicado: (2019)

Characteristics of new adult users of mepolizumab with asthma in the USA
por: Wu, Ann Chen, et al.
Publicado: (2021)

Daily Physical Activity in Asthma and the Effect of Mepolizumab Therapy
por: Panagiotou, Marios, et al.
Publicado: (2022)

Patient profiles and clinical utility of mepolizumab in severe eosinophilic asthma
por: Haldar, Pranabashis
Publicado: (2017)

Blood Eosinophil Depletion with Mepolizumab, Benralizumab, and Prednisolone in Eosinophilic Asthma
por: Moran, Angela M., et al.
Publicado: (2020)

Mepolizumab does not alter the blood basophil count in severe asthma
por: Wright, Adam Kelvin Alec, et al.
Publicado: (2019)

Role of mepolizumab in severe allergic asthma with vocal cord polyp
por: Karim, Azmat, et al.
Publicado: (2022)

Eosinophil‐derived neurotoxin and clinical outcomes with mepolizumab in severe eosinophilic asthma
por: Howarth, Peter, et al.
Publicado: (2020)

Self-Administered Mepolizumab in the Management of Severe Asthma: Usability and Patient Acceptance
por: Miyokawa, Reika, et al.
Publicado: (2020)

The clinical benefit of mepolizumab replacing omalizumab in uncontrolled severe eosinophilic asthma
por: Chapman, Kenneth R., et al.
Publicado: (2019)

Economic impact of mepolizumab in uncontrolled severe eosinophilic asthma, in real life()
por: Bagnasco, Diego, et al.
Publicado: (2021)

Response to Mepolizumab Treatment in Patients with Severe Eosinophilic Asthma and Atopic Phenotypes
por: Prazma, Charlene M, et al.
Publicado: (2021)

Outcomes over the first two years of treatment with mepolizumab in severe asthma
por: Elsey, Lynn, et al.
Publicado: (2021)

Mepolizumab improves clinical outcomes in patients with severe asthma and comorbid conditions
por: Gibson, Peter G., et al.
Publicado: (2021)

Treatment response with mepolizumab in severe eosinophilic asthma patients with previous omalizumab treatment
por: Magnan, A., et al.
Publicado: (2016)

Near-fatal asthma responsive to mepolizumab after failure of omalizumab and bronchial thermoplasty
por: Menzella, Francesco, et al.
Publicado: (2017)

Mepolizumab in the management of severe eosinophilic asthma in adults: current evidence and practical experience
por: Varricchi, Gilda, et al.
Publicado: (2016)

Eosinophils depletion therapy for severe asthma management following favorable response to mepolizumab
por: Matsuno, Osamu, et al.
Publicado: (2019)

Mepolizumab in the management of severe eosinophilic asthma in adults: current evidence and practical experience
por: Emma, Rosalia, et al.
Publicado: (2018)

Effectiveness and safety of mepolizumab in severe refractory eosinophilic asthma: results in clinical practice
por: Montero-Pérez, Olalla, et al.
Publicado: (2019)

Fungal sensitization and its relationship to mepolizumab response in patients with severe eosinophilic asthma
por: Wardlaw, Andrew, et al.
Publicado: (2020)

Update: Mepolizumab treatment in patients with severe eosinophilic asthma and prior omalizumab use
por: Albers, Frank C., et al.
Publicado: (2019)

Omalizumab and mepolizumab in the landscape of biological therapy for severe asthma in children: how to choose?
por: Giovannini, Mattia, et al.
Publicado: (2019)

Subcutaneous mepolizumab in children aged 6 to 11 years with severe eosinophilic asthma
por: Gupta, Atul, et al.
Publicado: (2019)

Real-World Effectiveness of Mepolizumab in Patients with Severe Asthma: An Examination of Exacerbations and Costs
por: Llanos, Jean-Pierre, et al.
Publicado: (2020)

Three cases of severe adolescent asthma treated with mepolizumab: lung function trajectories
por: Hoshi, Miyuki, et al.
Publicado: (2020)

Asthma Controller Medications for Children in Japan: Analysis of an Administrative Claims Database
por: Hamada, Shota, et al.
Publicado: (2015)

Evaluation of real-world mepolizumab use in severe asthma across Europe: the SHARP experience with privacy-preserving federated analysis
por: Kroes, Johannes A., et al.
Publicado: (2023)

Effectiveness of mepolizumab therapy on symptoms, asthma exacerbations, steroid dependence, and small airways in patients with severe eosinophilic asthma
por: YILMAZ, İnsu, et al.
Publicado: (2021)

Airway autoimmune responses in severe eosinophilic asthma following low-dose Mepolizumab therapy
por: Mukherjee, Manali, et al.
Publicado: (2017)

Severe eosinophilic asthma: from the pathogenic role of interleukin-5 to the therapeutic action of mepolizumab
por: Pelaia, Corrado, et al.
Publicado: (2017)

Severe uncontrolled asthma with bronchiectasis: a pilot study of an emerging phenotype that responds to mepolizumab
por: Carpagnano, Giovanna E, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_vopkfivg41h4sj5vslpis9s89a